The combination of Ceftriaxone (3rd generation Cephalosporin) and Sulbactam (beta-lactamase inhibitor) provides a solution for treatment of bacterial infections caused betalactam resistant pathogens.
Ceftriaxone has a broad spectrum of antibacterial activity which is beta-lactamase stable and exhibits excellent activity against Streptococcus pneumoniae, methicillin-susceptible staphylococci, Haemophilus influenzae, Moraxella catarrhalis and Neisseria sp. which are the most common cause of community acquired and hospital acquired infections.

Fantin et. al. in 1990, showed that the MIC and MBC of ceftriaxone was lowered by addition of sulbactam and the bacterial killing was enhanced proportionately.


Each Vial contains:

Sterile Ceftriaxone Sodium IP eq. to Cerftriaxone ..…… 1000 mg
Sterile Sulbactum Sodium USP eq. Sulbactum ……….…… 500mg


Transient elevations of BUN and serum creatinine have been observed, at recommended doses, the nephrotoxic potential of ceftriaxone is same as other cephalosporins. Since Ceftriaxone is excreted both via renal and bile patients with renal failure normally require no adjustment in dosage when usual doses of Ceftriaxone are administered.